E2F8 and prostate carcinoma: For the first time, we investigated the anti‐cancer properties of MA targeting prostate cancer in vitro and in vivo and demonstrated that MA abrogated the AR‐FL and its splice variance AR‐V7 transcription via inhibition of E2F8 function.